Pharmaceutical composition containing a 5-HT receptor antagonist and an H.sup.+ K.sup.+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
AssigneeGlaxo Group Limited
InventorMichael B. Tyers
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors and promotes gastric emptying in conjunction with an H.sup.+ K.sup.+ ATPase inhibitor in the treatment of gastrointestinal disorders.
Claims10
A pharmaceutical composition for use in human or veterinary medicine comprising an effective amount of a compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors and promotes gastric emptying, and an effective amount of a compound which is an H.sup.+ K.sup.+ ATPase inhibitor, with at least one physiologically acceptable carrier or excipient, wherein said compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors is a compound of formula (III):
- ##STR11## wherein R.sub.8 represents a C.sub.1-6 alkoxy or amino N-substituted by one or two groups selected from C.sub.1-6 alkyl and C.sub.3-8 cycloalkyl, or optionally N-substituted by C.sub.4-5 polymethylene;
- one of R.sub.9, R.sub.10 and R.sub.11 is hydrogen and the other two are independently selected from hydrogen, chloro, bromo, trifluoromethyl, hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-6 alkyl and amino;
- one of R.sub.12 and R.sub.13 represents hydrogen, C.sub.1-6 alkyl, phenyl or phenylC.sub.1-3 alkyl, which phenyl moieties may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3 or halogen, and the other of R.sub.12 and R.sub.13 is hydrogen or C.sub.1-6 alkyl;
- q is zero or an integer from 1 to 4;
- r is zero, or an integer from 1 to 3;
- and s is zero, 1 or 2,
- or a physiologically acceptable salt or solvate thereof, and said H.sup.+ K.sup.+ ATPase inhibitor is a 2-(pyridylmethylsulphinyl)benzimidazole, or a physiologically acceptable salt thereof.
A method of treating gastrointestinal disorders which comprises administering to a human or animal subject in need thereof an effective amount of a compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors and promotes gastric emptying in conjunction with an effective amount of a compound which is an H.sup.+ K.sup.+ ATPase inhibitor, wherein said compound which is an antagonist of 5-HT at 5-HT.sub.3 receptors is a compound of formula (III):
- ##STR12## wherein R.sub.8 represents a C.sub.1-6 alkoxy or amino N-substituted by one or two groups selected from C.sub.1-6 alkyl and C.sub.3-8 cycloalkyl, or optionally N-substituted by C.sub.4-5 polymethylene;
- one of R.sub.9, R.sub.10 and R.sub.11 is hydrogen and the other two are independently selected from hydrogen, chloro, bromo, trifluoromethyl, hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-6 alkyl and amino;
- one of R.sub.12 and R.sub.13 represents hydrogen, C.sub.1-6 alkyl, phenyl or phenylC.sub.1-3 alkyl, which phenyl moieties may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3 or halogen, and the other of R.sub.12 and R.sub.13 is hydrogen or C.sub.1-6 alkyl;
- q is zero or an integer from 1 to 4;
- r is zero, or an integer from 1 to 3;
- and s is zero, 1 or 2,
- or a physiologically acceptable salt or solvate thereof, and said H.sup.+ K.sup.+ ATPase inhibitor is a 2-(pyridylmethylsulphinyl)benzimidazole, or a physiologically acceptable salt thereof.
Dependencies are inferred from the claim text.